Company Long-Term Indebtedness: Ascentage Pharma Group International (AAPGV)

Graphic logo of Ascentage (AAPGV)

Ascentage Pharma Group (AAPGV) develops drugs targeting viral pathologies and neoplasms, leveraging licenses and the success of small molecule tests, as confirmed by the share price retrospective with the 0.05 indicator. Financial stability is tied to the outcomes of medical research in the absence of current operating revenue. The environmental profile is limited to laboratory operations, where the priorities are the safe disposal of chemicals and energy efficiency.

AAPGV Ascentage Pharma Group Ltd Company Long-Term Debts (01/25/2025 - 10/29/2026)

Ascentage Pharma Group Ltd - analytical breakdowns and key metrics (AAPGV)

- market price and analyst price targets:
Stock Price ascentage.com|AAPGV - Price Target Chart
- company stock exchange capitalization indicators:
Market Capitalization Ascentage Pharma|AAPGV - Enterprise Value
- balance sheet net asset value indicators:
Accounting Value per Share Ascentage Pharma|AAPGV - Book Capitalization|Market-to-Book Ratio ascentage.com|AAPGV - Aggregate Company Assets
- business debt structure and liquidity details:
All Debt to Shareholders' Equity Ratio Ascentage Pharma Group|AAPGV - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital Ascentage|AAPGV - Company Aggregate Debts|Debt to Book Value Ascentage Pharma|AAPGV - Company Long-Term Liabilities|Company Short-Term Debts Ascentage Pharma|Intermediate Coverage Ratio ascentage.com
- earnings and multiples data:
AAPGV - Net Profit
Summary company analytics:AAPGV - ascentage.com
Brand item of Ascentage

This metric captures the total credit obligations with a maturity of more than one year. Analyzing the history of the firm's long-term borrowings allows for the filtering of market noise to reveal the actual dynamics of the debt load. An increase in this metric indicates an expansion of liabilities to finance capital expenditures. For Ascentage Pharma Group (AAPGV), such loans are critical for establishing cutting-edge laboratories, providing the resource base for large-scale R&D research in oncology.

Competitor analysis for Ascentage Pharma Group

Company Long-Term Debts beigene.com ONC|HALO - Company Long-Term Debt|RVMD (Revolution Medicines Inc) - Company Long-Term Indebtedness|AAPG: Company Long-Term Debts|Company Long-Term Liabilities CG Oncology Therapeutics|URGN (UroGen Pharma Ltd.) - Company Long-Term Debts|Long-Term Debt bicara.com BCAX|Company Long-Term Debt Personalis (PSNL)|ERAS (Erasca Inc) - Company Long-Term Loans and Borrowings|Delcath - Company Long-Term Liabilities|Company Long-Term Loans and Borrowings YMAB|Aura Biosciences, Inc. - Company Long-Term Debts|Candel Therapeutics (CADL) - Company Long-Term Liabilities|ARAY (Accuray) - Company Long-Term Liabilities|SELLAS Life Sciences Group (SLS) - Company Long-Term Debts|Company Long-Term Debt Actuate Therapeutics, Inc|CTOR: Company Long-Term Loans and Borrowings|Company Long-Term Debts HURA|TARA - Long-Term Debt|Company Long-Term Debts FATE (Fate Therapeutics)|Company Long-Term Debts Aadi Bioscience, Inc. WHWK|TCRX - Company Long-Term Debt|Long-Term Debt Volume Champions Oncology CSBR|XBIT: Company Long-Term Debts|Company Long-Term Liabilities CEL-SCI|OSTX (OS Therapies) - Company Long-Term Debts|Long-Term Debt Radiopharm Theranostics Ltd RADX|Company Long-Term Debt Artiva Biotherapeutics, Inc. (ARTV)|adlainortye.com - Company Long-Term Indebtedness|Veru Inc. - Company Long-Term Liabilities|Amount of Long-Term Liabilities TPST (tempesttx.com)|Xilio - Company Long-Term Debts|RENB - Company Long-Term Debts|MURA: Company Long-Term Debts|Long-Term Indebtedness Kairos Pharma KAPA|OKUR (OnKure Therapeutics, Inc.) - Company Long-Term Debts|Long-Term Debt CytoMed GDTC|Company Long-Term Liabilities CRIS (Curis, Inc.)|APLM (apollomicsinc.com) - Company Long-Term Loans and Borrowings|Company Long-Term Debt Tharimmune Corp THAR|ADVB (Advanced Biomed Inc.) - Long-Term Liabilities|Genprex, Inc. - Company Long-Term Debts|Company Long-Term Loans and Borrowings CLDI (Calidi Biotherapeutics)|SBFM: Company Long-Term Debts|Xenetic Biosciences, Inc. (XBIO) - Company Long-Term Debts|Company Long-Term Debt Salarius|PPBT: Company Long-Term Loans and Borrowings|Company Long-Term Debt American Oncology Network (AONC)|Company Long-Term Liabilities beigene.com BGNE|Company Long-Term Debts CKPT (Checkpoint Therapeutics, Inc.)|Company Long-Term Debts Elevation Oncology Inc. ELEV|ICAD: Company Long-Term Liabilities|Company Long-Term Loans and Borrowings IKNA (Ikena Oncology, Inc.)|NTBL: Company Long-Term Debts|Long-Term Indebtedness Viracta Therapeutics, Inc. VIRX|Company Long-Term Debt MorphoSys|NAYA: Company Long-Term Loans and Borrowings